Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Coding Corner Question: Billing Infusion Procedure with JW Modifier

From the College  |  Issue: April 2017  |  April 20, 2017

Africa Studio/shutterstock.com

Africa Studio/shutterstock.com

An 82-year-old female established patient diagnosed with ankylosing spondylitis in multiple joints returns to the office for her second infliximab infusion. She denies any fevers, cough or concurrent illness. Her joint pain is 7 on a scale of 1–10. She complains of achy pain in the cervical, lumbar and sacral regions of her spine. She is also on a non-steroidal anti-inflammatory drug. No changes were made to her medications. She weighs 172 lbs., her height is 5’5”, and her BMI is 29. Her past history, family history and social history have not changed since her first infusion.

She is administered 50 mg of diphenhydramine as a prophylactic measure against possible drug reaction. Her IV port is started at 10:10 a.m., and an IV infliximab 400 mg infusion is started at 10:25 a.m. Twenty-two minutes into the infusion, the patient has a severe reaction with shortness of breath. The infusion is stopped at 10:47 a.m., and the saline hydration is pushed at 10:57 a.m.—to flush the infliximab—and is completed at 11:28 a.m. She is seen by the physician, and a detailed exam is performed with medical decision making of moderate complexity. When the infusion was discontinued, there was drug wastage of 360 mg of infliximab.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

How should this patient encounter be coded?

Share: 

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodinginfliximabInfusionoffice visitpatient carePractice Managementrheumatologistrheumatology

Related Articles

    Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier

    April 20, 2017

    Take the challenge. CPT: 99214-25, 96413, 96375, 96361-59, J1745 x 4 J1745 JW* x 36, J1200 x1 ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEICD-10: M45.09, T50.995A, R06.02, E66.3, Z68.2 Rationale Modifier 25 is appropriate to use because it indicates the patient received a significant, separately identifiable E/M service on the same day as the infliximab infusion. This…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Reading Rheum

    July 1, 2007

    Handpicked Reviews of Contemporary Literature

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences